Two studies showed that fedratinib in combination with erlotinib (EGFR tyrosine kinase inhibitor) decreased STAT3 activation and increased apoptosis in erlotinib-resistant NSCLC cells and inhibited tumor growth in in vivo murine models[155,156]. Here, STAT3 is linked to non-small cell lung carcinoma.